<code id='A6DB25B764'></code><style id='A6DB25B764'></style>
    • <acronym id='A6DB25B764'></acronym>
      <center id='A6DB25B764'><center id='A6DB25B764'><tfoot id='A6DB25B764'></tfoot></center><abbr id='A6DB25B764'><dir id='A6DB25B764'><tfoot id='A6DB25B764'></tfoot><noframes id='A6DB25B764'>

    • <optgroup id='A6DB25B764'><strike id='A6DB25B764'><sup id='A6DB25B764'></sup></strike><code id='A6DB25B764'></code></optgroup>
        1. <b id='A6DB25B764'><label id='A6DB25B764'><select id='A6DB25B764'><dt id='A6DB25B764'><span id='A6DB25B764'></span></dt></select></label></b><u id='A6DB25B764'></u>
          <i id='A6DB25B764'><strike id='A6DB25B764'><tt id='A6DB25B764'><pre id='A6DB25B764'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:fashion    Page View:42811

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In